What is LensGen?
Headquartered in Irvine, California, LensGen is dedicated to restoring youthful vision for patients suffering from cataracts and presbyopia. The company's flagship technology, the Juvene® fluid-optic intraocular lens, is designed to correct vision errors and eliminate the need for spectacles. This focus on spectacle independence positions LensGen within the rapidly growing ophthalmic device market, addressing a substantial patient population seeking improved visual acuity and quality of life.
How much funding has LensGen raised?
LensGen has raised a total of $31.9M across 3 funding rounds:
Private Equity
$950K
Series A
$21M
Debt
$10M
Private Equity (2013): $950K, investors not publicly disclosed
Series A (2017): $21M, investors not publicly disclosed
Debt (2020): $10M supported by HOYA Corporation
Key Investors in LensGen
HOYA Corporation
HOYA Corporation is a key participant in this funding round, suggesting a strategic alignment with LensGen's vision correction technologies.
What's next for LensGen?
The recent major strategic investment, following earlier rounds of private equity and Series A financing, indicates LensGen is entering a critical phase of scaling its operations and commercializing its Juvene® intraocular lens. This enterprise-level capital infusion is likely earmarked for advancing clinical trials, securing regulatory approvals, and building out manufacturing and distribution capabilities. The company's trajectory suggests a strong potential for market penetration and significant impact on the ophthalmic industry.
See full LensGen company page
